p16基因蛋白在宫颈癌中的表达

目的:观察细胞周期调节蛋白抑制因子p16在宫颈癌组织中的表达,并探讨其与宫颈癌的关系。方法:应用SP免疫组化法检测11例正常宫颈上皮,9例宫颈上皮内瘤样病变(CIN)和48例宫颈癌石蜡包埋组织切片中p16基因蛋白表达情况。统计处理用SSPS10.0软件分析系统。结果:在正常宫颈上皮、CIN和宫颈癌组织中,p16表达的阳性率分别为18.18％、66.67％、87.50％。从正常宫颈到CIN到宫颈癌组织中p16表达呈现逐渐升高的趋势。宫颈癌组织p16表达明显高于正常宫颈组织,具有极显著性差异(P<0.001),CIN和正常宫颈上皮比较,p16表达无显著性差异(P>0.05)。p16表达与宫颈癌的临床分期、组织类型、分化程度以及淋巴结转移均无显著相关性(P>0.05)。结论:细胞周期调节蛋白抑制因子p16基因蛋白高表达参与宫颈癌的癌变过程。

Expression of p16 and Its Involvement in Carcinogenesis of Cervical Carcinoma

Objective: This study was to observe the expression of the cell regulator cyclinD1-dependent kinase inhibitor p16 in normal cervixes, CINs, and cervical carcinomas, and to evaluate tentatively the relationship between p16 expression alteration and the cervical carcinomas. Methods: Immunohistochemical analysis using an-ti-p16 antibodies was done on 11 paraffin sections of normal cervixes, 9 of CINs, and 48 of cervical carcinomas. All data were processed by using SPSS10 software. Results: The results showed that 18.18% of normal cervixes, 66.67% of CINs, and 87.50% of cervical carcinomas expressed p16. The expression of p16 was significantly higher in cervical carcinomas than in normal cervixes (P < 0.01). No statistical difference of p16 expression was found between normal cervix and CIN, nor was the positive correlation between p16 expression and clinico-pathological parameters observed. Conclusion: These data suggested that overexpression of p16 seems to be involved in the carcinogenesis of cervix. The relationship between the over expression of p16 and the infiltration, metastasis and prognosis of the patients with cervical carcinomas needs to be further studied.